The potential of the bone marrow microenvironment as a therapeutic target in MDS was recently demonstrated by the approval of Luspatercept, an activin receptor type IIB, for the treatment of low-risk MDS. The gene discussed is ACVR2B; the disease is myelodysplastic syndrome.